STAAR Surgical (STAA) Expected to Post Earnings on Wednesday

STAAR Surgical (NASDAQ:STAA) is expected to announce its earnings results after the market closes on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.02 per share and revenue of $77.47 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.

STAAR Surgical Price Performance

Shares of STAA opened at $21.88 on Wednesday. The stock’s fifty day moving average price is $23.94 and its two-hundred day moving average price is $29.33. STAAR Surgical has a 1 year low of $21.13 and a 1 year high of $52.68. The firm has a market cap of $1.08 billion, a PE ratio of 49.73 and a beta of 0.62.

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. acquired 53,500 shares of the company’s stock in a transaction on Monday, December 16th. The stock was acquired at an average price of $24.24 per share, for a total transaction of $1,296,840.00. Following the acquisition, the insider now owns 10,821,931 shares in the company, valued at $262,323,607.44. This represents a 0.50 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders have purchased 105,876 shares of company stock valued at $2,487,168 in the last ninety days. Company insiders own 1.00% of the company’s stock.

Wall Street Analyst Weigh In

STAA has been the topic of several research analyst reports. Stephens raised shares of STAAR Surgical to a “hold” rating in a report on Monday, December 2nd. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research report on Tuesday, January 7th. Finally, Canaccord Genuity Group dropped their price target on STAAR Surgical from $31.00 to $28.00 and set a “hold” rating for the company in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, STAAR Surgical presently has a consensus rating of “Hold” and a consensus price target of $42.83.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.